BACKGROUND: Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Studies of interpretive variation according to grade are limited. METHODS: A national sample of 115 pathologists interpreted 240 breast pathology test set cases in the Breast Pathology Study and their interpretations were compared to expert consensus interpretations. We assessed agreement of pathologists\u27 interpretations with a consensus reference diagnosis of DCIS dichotomised into low- and high-grade lesions. Generalised estimating equations were used in logistic regression models of rates of under- and over-interpretation of DCIS by grade. RESULTS: We evaluated 2097 independent interpretations of DCIS (512 low-grade DCIS and 1585 high-grade...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
AbstractObjectivesTo compare the underestimation of ductal carcinoma in situ (DCIS) vs DCIS with “po...
Funder: Cancer Research UK and by KWF Kankerbestrijding (ref. C38317/A24043)BACKGROUND: The Sloane a...
BACKGROUND: Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Stud...
Purpose: A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into inva...
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due ...
Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
Importance: While the prevalence of ductal carcinoma in situ (DCIS) of the breast has increased subs...
BACKGROUND: In the absence of definitive data about the natural history of DCIS the appropriateness ...
Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCI...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
OBJECTIVES: Since most patients with ductal carcinoma in situ (DCIS) of the breast are treated upon ...
© 2019 John Wiley & Sons Ltd Aims: Ductal carcinoma in situ (DCIS) of the breast is a heterogeneou...
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer that can progress into invasive duct...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
AbstractObjectivesTo compare the underestimation of ductal carcinoma in situ (DCIS) vs DCIS with “po...
Funder: Cancer Research UK and by KWF Kankerbestrijding (ref. C38317/A24043)BACKGROUND: The Sloane a...
BACKGROUND: Diagnostic agreement among pathologists is 84% for ductal carcinoma in situ (DCIS). Stud...
Purpose: A considerable part of ductal carcinoma in situ (DCIS) lesions may never progress into inva...
The prognostic value of cytonuclear grade in ductal carcinoma in situ (DCIS) is debated, partly due ...
Ductal carcinoma in situ of the breast is a non-obligate precursor of invasive breast cancer, and at...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
Importance: While the prevalence of ductal carcinoma in situ (DCIS) of the breast has increased subs...
BACKGROUND: In the absence of definitive data about the natural history of DCIS the appropriateness ...
Nuclear grade is an important indicator of the biological behaviour of ductal carcinoma in situ (DCI...
AIMS: Robust prognostic markers for ductal carcinoma in situ (DCIS) of the breast require high repro...
OBJECTIVES: Since most patients with ductal carcinoma in situ (DCIS) of the breast are treated upon ...
© 2019 John Wiley & Sons Ltd Aims: Ductal carcinoma in situ (DCIS) of the breast is a heterogeneou...
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer that can progress into invasive duct...
PURPOSE: To compare the histological grades of screen detected and non-screen detected ductal carcin...
AbstractObjectivesTo compare the underestimation of ductal carcinoma in situ (DCIS) vs DCIS with “po...
Funder: Cancer Research UK and by KWF Kankerbestrijding (ref. C38317/A24043)BACKGROUND: The Sloane a...